Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
<p>Cell line and PDX genetics</p>
Saved in:
Similar Items
-
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
by: Elizabeth R. Tucker (15053624)
Published: (2025) -
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
by: Elizabeth R. Tucker (15053624)
Published: (2025) -
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
by: Elizabeth R. Tucker (15053624)
Published: (2025) -
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
by: Elizabeth R. Tucker (15053624)
Published: (2025) -
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
by: Elizabeth R. Tucker (15053624)
Published: (2025)